PMV participates in 71 million euros Series C round of Biocartis

PMV participates in 71 million euros Series C round of Biocartis.

Funds will be used to commercialize a fully automated, compact molecular diagnostics system designed to drive the widespread adoption of personalized medicine and other diagnostic applications including the fight against infectious disease. Biocartis, founded in 2007, has so far raised over 100 million euros. With its investment in Biocartis, PMV further executes its strategy to be one of Flanders’ leading venture capital investors in biotech breakthrough technologies.

We refer to the news section on www.biocartis.com for more information.